Annual Short Term Debt
N/A
31 December 2023
Summary:
Halozyme Therapeutics annual short term debt is not available.HALO Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Short Term Debt
N/A
30 September 2024
Summary:
Halozyme Therapeutics quarterly short term debt is not available.HALO Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Short Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
HALO Short Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time |
Halozyme Therapeutics Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $13.33 M(-85.1%) | $13.33 M(+0.1%) |
| Sept 2022 | - | $13.31 M(-86.6%) |
| June 2022 | - | $99.05 M(+10.6%) |
| Mar 2022 | - | $89.55 M(+0.1%) |
| Dec 2021 | $89.42 M(-77.5%) | $89.42 M(+0.2%) |
| Sept 2021 | - | $89.25 M(+0.1%) |
| June 2021 | - | $89.17 M(+0.1%) |
| Mar 2021 | - | $89.04 M(-77.6%) |
| Dec 2020 | $397.23 M(+1932.7%) | $397.23 M(>+9900.0%) |
| Mar 2020 | - | $2.86 M(-85.4%) |
| Dec 2019 | $19.54 M(-78.6%) | $19.54 M(-64.2%) |
| Sept 2019 | - | $54.54 M(-23.1%) |
| June 2019 | - | $70.88 M(-18.2%) |
| Mar 2019 | - | $86.66 M(-5.3%) |
| Dec 2018 | $91.51 M(+18.5%) | $91.51 M(+3.4%) |
| Sept 2018 | - | $88.52 M(+1.8%) |
| June 2018 | - | $86.97 M(+5.5%) |
| Mar 2018 | - | $82.46 M(+6.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $77.21 M(+343.9%) | $77.21 M(+25.7%) |
| Sept 2017 | - | $61.43 M(+35.0%) |
| June 2017 | - | $45.52 M(+53.8%) |
| Mar 2017 | - | $29.60 M(+70.2%) |
| Dec 2016 | $17.39 M(-20.4%) | $17.39 M(+40.3%) |
| Sept 2016 | - | $12.39 M(+276.9%) |
| June 2016 | - | $3.29 M(-88.0%) |
| Mar 2016 | - | $27.42 M(+25.4%) |
| Dec 2015 | $21.86 M | $21.86 M(+39.3%) |
| Sept 2015 | - | $15.70 M(+62.6%) |
| June 2015 | - | $9.66 M(+158.9%) |
| Mar 2015 | - | $3.73 M(-63.0%) |
| Sept 2014 | - | $10.07 M(+62.4%) |
| June 2014 | - | $6.20 M(+158.0%) |
| Mar 2014 | - | $2.40 M(-59.7%) |
| Sept 2013 | - | $5.97 M(+63.9%) |
| June 2013 | - | $3.64 M(+167.5%) |
| Mar 2013 | - | $1.36 M |
FAQ
- What is the all time high annual short term debt for Halozyme Therapeutics?
- What is the all time high quarterly short term debt for Halozyme Therapeutics?
What is the all time high annual short term debt for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual short term debt is $397.23 M
What is the all time high quarterly short term debt for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly short term debt is $397.23 M